Endocrine Oncology
LightNews LightNews
banner
endocrineoncology.bsky.social
Endocrine Oncology
@endocrineoncology.bsky.social
120 followers 83 following 65 posts
An open-access journal from society-owned publisher, Bioscientifica. Publishing research and reviews on the interplay between hormones and cancer, and related topics. Visit eo.bioscientifica.com to learn more.
Posts Replies Media Videos
endocrineoncology.bsky.social
Call for Papers: Tumour Heterogeneity in Neuroendocrine Neoplasms

We invite you to contribute to our latest Special Collection exploring the complexity of tumour heterogeneity in neuroendocrine neoplasms (NENs).

eo.bioscientifica.com/page/NENs/tumour-heterogeneity-in-neuroendocrine-neoplasms
Endocrine Oncology logo. Special Collection: Tumour Heterogeneity in Neuroendocrine Neoplasms. Open Access logo. Open for Submissions. Contribute an article! Collection Editors: Prof. Louis de Mestier - Department of Pancreatology & Digestive Oncology. Universite Paris-Cite, Beaujon Hospital (APHP), Clichy, France Prof. Jerome Cros - Department of Pathology, Universite Paris-Cite, Beaujon Hospital (APHP), Clichy, France
November 18, 2025 at 8:40 AM
endocrineoncology.bsky.social
Next week, Society of Endocrinology will host the Hormone-Dependent Cancer Conference.

As sponsors, we've launched a Special Collection to complement the event. We invite research submissions that advance our understanding of hormone-dependent cancers.
📧 eo@bioscientifica.com
🌐 bit.ly/4oyll2v
Endocrine Oncology. Open Access. Special Collection: Hormone-Dependent Cancers: from Bench to Bedside. Collection Editors: Dr Claire Fletcher - Assistant Professor, Imperial College London, UK Dr Adriana Buskin - Prostate Cancer UK Research Fellow, Newcastle University Centre for Cancer, UK Dr Emma Scott - Research Fellow, Newcastle University Centre for Cancer, UK
November 11, 2025 at 10:51 AM
endocrineoncology.bsky.social
New research by K Wang et al. suggest that paltusotine, a novel somatostatin analogue, could be continued during peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs).

🔗 Explore the findings: doi.org/10.1530/EO-25-0041
Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours in Endocrine Oncology Authors: Katharina Wang et al. Open Access. Figure 1. (A) 18F-SiTATE uptake assay using BON-1 SSTR2 cells after treatment with either paltusotine or octreotide. Cellular uptake was measured after (B) 30 min, (C) 120 min and (D) 240 min. DOTATATE acetate was used as the blocked control. The data are depicted as mean ± SD of four duplicate experiments. Molar concentrations: 100× (7.3–25.4 nM), 1,000× (73–254 nM), 2,000× (146–508 nM). Significantly lower radioligand uptake compared to the unblocked control *P < 0.05, **P < 0.01, ***P < 0.001. Endocrine Oncology 5, 1; 10.1530/EO-25-0041 Published by Bioscientifica. Society of Endocrinology.
November 4, 2025 at 11:17 AM
endocrineoncology.bsky.social
Cytoreductive surgery is standard for metastatic phaeochromocytomas & paragangliomas. 177Lu‑DOTATATE PRRT could offer a safe, effective option for inoperable cases.

Kalyan Mansukhbhai Shekhda et al. report encouraging PFS & improved health-related QoL following PRRT.

🔗 doi.org/10.1530/EO-25-0019
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence in Endocrine Oncology. By Kalyan Mansukhbhai Shekhda et al. Figure 1. Flow chart of inclusion process of study cohort. Endocrine Oncology 5, 1; 10.1530/EO-25-0019. Open Access. Society for Endocrinology. Published by Bioscientifica.
October 28, 2025 at 9:49 AM
endocrineoncology.bsky.social
🔬 Molecular testing is changing how we assess thyroid cancer risk.

New research by Alexander R Goldberg et al. explores the clinical & molecular characteristics of cytologically non-malignant thyroid tumors with multiple high-risk mutations, revealing aggressive behaviour.

#ThyroidCancer
Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes in Endocrine Oncology. By Alexander R Goldberg et al. Open Access Figure 1. Case 1 histology and molecular testing: tumor subpopulations with relative hypocellularity (T1), hypercellularity (T2), and an intermediate area (T3). Each section was further analyzed by molecular testing and compared to the sternal metastasis molecular testing. Endocrine Oncology 5, 1; 10.1530/EO-25-0054. Published by bioscientifica. Society for Endocrinology.
October 21, 2025 at 8:04 AM
endocrineoncology.bsky.social
🧬 New research by Julio Ricarte Filho et al. provides the first comprehensive molecular and immune comparison of oncocytic thyroid cancer and follicular thyroid cancer, offering new insights into their biological differences.

👉 Read the full research: doi.org/10.1530/EO-25-0026
Macrophage abundance in oncocytic thyroid cancer is associated with PD-L1 expression in Endocrine Oncology. By Julio C Ricarte-Filho et al. Open Access. Published by Bioscientifica. Society for Endocrinology. Figure 1 (A) Volcano plot highlighting mRNAs differentially expressed between (OTCs, n = 12) and non-neoplastic thyroids (n = 9). The cyan dots denote downregulated gene expression in OTC, and the purple dots denote upregulated gene expression in OTC. Gray dots denote gene expression without significant differences (fold change ≥2 and FDR ≤0.05). (B) Top DEGs between OTC (blue) and non-neoplastic thyroids (yellow). Plots show top five upregulated genes (top) and downregulated genes (bottom) in oncocytic tumors. (C) Functional enrichment analysis of upregulated genes reveals enrichment for genes related to metabolic pathways (KEGG database), carbon metabolism, and others. (D) Heatmap displaying increased mRNA expression of metabolic genes in OTC vs non-neoplastic thyroids. Red: upregulated genes; blue: downregulated genes. FC: fold change. Citation: Endocrine Oncology 5, 1; 10.1530/EO-25-0026
October 16, 2025 at 1:19 PM
Reposted by Endocrine Oncology
thebacr.bsky.social
Explore influential studies in endocrine-related cancers published in Endocrine Oncology, a society-owned journal, covering topics from prolactinomas to thyroid tumours 👉 eo.bioscientifica.com/page/top-cited/top-cited-articles

Endocrine Oncology is proudly endorsed by BACR.
eo.bioscientifica.com
October 3, 2025 at 12:18 PM
endocrineoncology.bsky.social
New research by Kalyan Vamshi Vemulapalli et al. demonstrates that ⁶⁸Ga-DOTA-TATE PET/CT offers a higher detection rate for dpNETs in MEN1 patients compared to conventional CT and MRI - resulting in significant changes to clinical management.

📖 Read the full article: doi.org/10.1530/EO-25-0060
68Ga-DOTA-TATE PET/CT improves accuracy and guides management in multiple endocrine neoplasia type 1 (MEN-1) patients with suspected duodeno-pancreatic neuroendocrine tumours in Endocrine Oncology. By Kalyan Vamshi Vemulapalli et al. Figure 1. (A) MRI abdomen: difficult to identify pancreatic lesion on MRI. (B) 68Ga-DOTA-TATE PET/CT avid pancreatic body lesion. Endocrine Oncology 5, 1; 10.1530/EO-25-0060 Published by Bioscientifica. Society for Endocrinology. Open Access.
September 30, 2025 at 7:59 AM
endocrineoncology.bsky.social
Systemic therapy for metastatic adrenocortical carcinoma (mACC) remains a challenge.

A new meta-analysis by S Shekar et al. synthesises prospective trial data to:
💡 Benchmark survival and response
💡 Compare treatment efficacy
💡 Identify gaps for future trials

🔗 doi.org/10.1530/EO-25-0027
Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials in Endocrine Oncology. By S Shekar et al. Figure 2. Forest plot of pooled ORRs in metastatic adrenocortical carcinoma, stratified by treatment subgroup. Endocrine Oncology 5, 1; 10.1530/EO-25-0027 Published by bioscientifica. Society for Endocrinology.
September 25, 2025 at 9:45 AM
endocrineoncology.bsky.social
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.

The NETRF Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.

Register now: bit.ly/4nQ9goU

#NETresearch #cancerresearch
Register Now! 2025 Margie & Robert E. Petersen. Neuroendocrine Tumor Research Symposium. Breakthroughs today, cures tomorrow. Location: Boston, Massachusetts. Date: November 17-19.
September 24, 2025 at 7:40 AM
endocrineoncology.bsky.social
🆕 A retrospective case series by Eleni Armeni et al. from Royal Free Hospital explores the diagnostic & therapeutic complexities of glucagonomas, offering a valuable reference point for clinicians & researchers navigating the field.

🔗Read the article: doi.org/10.1530/EO-24-0083
Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas in Endocrine Oncology. By Eleni Armeni et al. Published by Bioscientifica. Society for Endocrinology. Figure 1: Third-line treatment: median values of PFS comparing PRRT vs other agents (molecular agents or chemotherapy). Endocrine Oncology 5, 1; 10.1530/EO-24-0083
September 16, 2025 at 8:02 AM
endocrineoncology.bsky.social
🌐 Endocrine Oncology has joined LinkedIn!

We're excited to connect with the global endocrine oncology community in a new space.

Follow us for the latest journal articles, special collections and key updates.

🌐 linkedin.com/company/endocrine-oncology/
Follow us on LinkedIn. Endocrine Oncology. LinkedIn logo.
September 12, 2025 at 10:42 AM
endocrineoncology.bsky.social
New research by Kim Dijke et al. (@nkinl.bsky.social) highlights the differences in disease course of appendiceal NETs & appendiceal goblet cell adenocarcinomas, supporting the exclusion of aGCAs from the group of NENs in the 5th #WHO classification.

Read the research: doi.org/10.1530/EO-25-0028
Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas in Endocrine Oncology. By Kim Dijke et al. Figure 1. Kaplan–Meier curve for PFS in patients with aNET and aGCA. Citation: Endocrine Oncology 5, 1; 10.1530/EO-25-0028. Published by Bioscientifica. Society for Endocrinology. Open Access.
September 9, 2025 at 1:33 PM
Reposted by Endocrine Oncology
endocancer.bsky.social
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!

We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.

📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
Special Collection: Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms. Endocrine-Related Cancer. Collection Editors: Dr. Sunita M. C. De Sousa, MD, PhD Dr. Frederic Castinetti, MD, PhD Dr. Henriett Butz, MD, PhD Dr. Adrian F. Daly, MD, PhD
September 5, 2025 at 3:07 PM
endocrineoncology.bsky.social
🆕 Tumour Heterogeneity in Neuroendocrine Neoplasms Special Collection #NENs

We’re seeking cutting-edge research on the biological & clinical characterisation of NEN heterogeneity, highlighting its impact on prognosis & treatment outcomes.

🌐 More info: bit.ly/4lWsJTc
📢 Submit: eo@bioscientifica.com
Endocrine Oncology. Special Collection. Tumour Heterogeneity in Neuroendocrine Neoplasms. Open Access. Open for Submission. Guest Editors: Professor Louis de Mestier and Professor Jérôme Cros
September 3, 2025 at 1:27 PM
endocrineoncology.bsky.social
🧬 A new systematic review and meta-analysis by M P Aguiar et al. links estrogen-related gene polymorphisms to ovarian cancer occurrence/susceptibility, uncovering variants in CYP17A1, COMT and GSTP1 that may be associated with risk.

🔗 Explore the review #OpenAccess: doi.org/10.1530/EO-25-0007
Impact of single nucleotide variants in estrogen genes on ovarian cancer risk: a systematic review and meta-analysis in Endocrine Oncology. By M P Aguiar et al. Published by bioscientifica. Society for Endocrinology. Open Access.
September 2, 2025 at 11:54 AM
Reposted by Endocrine Oncology
endocancer.bsky.social
🌱Endocrine-Related Cancer is officially on LinkedIn!

Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.

🌐 linkedin.com/company/endocrine-related-cancer/

#MedSky #CancerResearch #EndocrineOncology #HormoneCancers
Follow us on LinkedIn. LinkedIn logo. Endocrine-Related Cancer logo.
August 29, 2025 at 10:31 AM
endocrineoncology.bsky.social
🔬 Latest research by Lara Toffoli et al. investigates the impact of FAK inhibition on GI neuroendocrine tumors (GI-NETs) demonstrating its pivotal role in pathogenesis of GI-NETs & supporting its therapeutic targeting.

👉 Read the full article: doi.org/10.1530/EO-2...
FAK inhibition disrupts tumor growth, apoptosis, and transcriptional regulation in GI-NETs in Endocrine Oncology. By Lara Toffoli et al. Open Access. Published by bioscientifica, Society for Endocrinology. Figure 6. Dual role of FAK in GI-NETs. Schematic model illustrating the dual role of FAK in gastrointestinal neuroendocrine tumors (GI-NETs). FAK regulates oncogenic pathways through both its kinase-dependent and scaffold (kinase-independent) functions. On the left, Y15 and PROTAC-FAK inhibit the kinase activity of FAK, leading to reduced ERK1/2 signaling and downstream suppression of RB1 transcription. On the right, PROTAC-FAK uniquely targets the scaffold function of FAK, which includes its nuclear translocation and putative interaction with histone acetyltransferases (HATs) or histone deacetylases (HDACs). This interaction may alter chromatin accessibility and modulate epigenetic control of RB1 expression, independent of classical phosphorylation signaling. This model supports a dual mechanism by which FAK promotes GI-NET cell survival and gene regulation. Created in BioRender. Gagliano T (2025) (https://BioRender.com/ddyjxrf). Endocrine Oncology 5, 1; 10.1530/EO-25-0052.
August 26, 2025 at 7:48 AM
Reposted by Endocrine Oncology
socendocrinology.bsky.social
Your research can help advance hormone-dependent cancer treatment and improve patient care. Abstract submissions close Monday 15 Sept: bit.ly/4fqWdqL
August 14, 2025 at 6:55 AM
Reposted by Endocrine Oncology
terrygag.bsky.social
Our study on FAK inhibition in GI-NETs reveals its dual role in tumor growth, invasion, and even epigenetic regulation.
Grateful to my team for their dedication, and to all colleagues, collaborators, and friends who supported us along the way. 🙏
📄 Open Access: eo.bioscientifica.com/view/journal...
eo.bioscientifica.com
August 14, 2025 at 11:33 AM
Reposted by Endocrine Oncology
terrygag.bsky.social
💗 Proud of my young research group 💗
Despite limited resources and many challenges, we published our latest work in @endocrineoncology.bsky.social — an emerging journal with a distinguished editorial board of leading experts.
#CancerResearch #FAK #NeuroendocrineTumors #TeamScience
August 14, 2025 at 11:33 AM
endocrineoncology.bsky.social
Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.

Learn more: mierf.org/to-apply/

#neuroendocrinecancer #earlycareerresearcher
The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs). Submissions Now Open. Proposal Due August 31, 2025. ERF Logo. NETRF logo.
August 15, 2025 at 8:45 AM
endocrineoncology.bsky.social
📈Incidence & prevalence of neuroendocrine neoplasms continues to rise globally.

A new review by Jessica Mangion et al. explores global epidemiological data, reviewing trends & differences in incidence rates to improve our understanding of this rise.

🔗 doi.org/10.1530/EO-25-0039
Epidemiological insights and survival patterns in neuroendocrine neoplasia: a geographic perspective in Endocrine Oncology. By Jessica Mangion, Josanne Vassallo, and Mark Gruppetta. Society of Endocrinology. Published by bioscientifica. Open Access. Figure 2: The global distribution of gastroenteropancreatic (GEP) NEN and lung NEN based on SIR. Endocrine Oncology 5, 1; 10.1530/EO-25-0039
August 12, 2025 at 7:54 AM
endocrineoncology.bsky.social
🔍Somatostatin analogues (SSA) can unmask insulinoma in presumed non-functional GEP-NETs.

A new case report by Isuru Gamage et al. (@petermaccc.bsky.social‬) presents two cases where SSA unmasked hypoglycaemia due to insulinoma.

📖 Check out the full report: doi.org/10.1530/EO-2...
Endocrine Oncology. Society of Endocrinology. Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours in Endocrine Oncology. By Isuru Gamage et al. Open Access, published by bioscientifica. Figure 1. Molecular imaging phenotype of insulinoma cases. Case 1 and case 2 both demonstrate a similar imaging phenotype, with the GaTate PET/CT demonstrating ≥ Krenning 3 (3 = higher than liver, 4 = higher than spleen) SSTR expression in hepatic metastatic disease. Some hepatic lesions also have mild-to-moderate FDG avidity. Case 1: primary pancreatic lesion denoted on GaTate maximum intensity projection (MIP) by orange arrow, with the remaining disease located in the liver. The moderate FDG uptake associated with the pancreatic primary is obscured by renal activity on the MIP. Axial panels demonstrate liver disease with Krenning 3–4 SSTR expression with mild-to-moderate FDG avidity. Case 2: post distal pancreatectomy and splenectomy. . No local pancreatic recurrence, multifocal hepatic metastatic disease. Axial panels demonstrate hepatic disease with Krenning 4 SSTR expression and a lesion with mild-to-moderate FDG avidity. Bilateral pleural effusions are seen on low-dose CT.
August 7, 2025 at 9:43 AM
endocrineoncology.bsky.social
🧠A new systematic review and meta-analysis by Tatiana Tselovalnikova et al. highlights why long-term monitoring is crucial after cranial irradiation as growth hormone deficiency can develop years post-treatment.

👉Read the full article: doi.org/10.1530/EO-25-0025
New Research: Prevalence of growth hormone deficiency in brain tumor survivors: a systematic review and meta-analysis in Endocrine Oncology. Authors: Tatiana Tselovalnikova et al. Open Access. Published by Bioscientifica. Society for Endocrinology.
July 29, 2025 at 8:35 AM